US Stock MarketDetailed Quotes

CNTX Context Therapeutics

Watchlist
  • 1.3800
  • -0.0020-0.14%
Close Mar 28 16:00 ET
  • 1.3700
  • -0.0100-0.72%
Post 18:16 ET
22.03MMarket Cap-920P/E (TTM)

About Context Therapeutics Company

Context Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is dedicated to improving the lives of women living with cancer. It engages in developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers. The firm's robust clinical program for candidate onapristone extended release (ONA-XR) comprises three Phase 2 clinical trials and one Phase 1b/2 clinical trial in hormone-driven breast, ovarian and endometrial cancer, as well as two Phase 0 biomarker pharmacodynamic trials in breast cancer. Its ONA-XR is a novel, first-in-class small molecule under development as a complete antagonist of the progesterone receptor, a key unchecked mechanism in hormone-driven women?s cancers. The company was founded by Martin Lehr and Felix Kim in April 2015 and is headquartered in Philadelphia, PA.

Company Profile

SymbolCNTX
Company NameContext Therapeutics
Listing Date10/20/2021
Issue Price5.00
Founded2015
CEOMr. Martin Lehr
MarketNASDAQ
Employees5
Securities TypeOrdinary Shares
Fiscal Year Ends12-31
Address2001 Market Street,Unit 15,Suite 3915
CityPhiladelphia
ProvincePennsylvania
CountryUnited States of America
Zip Code19103
Phone1-267-225-7416

Company Executives

  • Name
  • Position
  • Salary
  • Martin Lehr
  • Chief Executive Officer, President and Director
  • 1.06M
  • Jennifer Minai-Azary
  • Chief Financial Officer, Principal Accounting Officer and Treasurer
  • 680.67K
  • Alex Levit
  • Chief Legal Officer and Corporate Secretary
  • 653.10K
  • Dr. Tarek Sahmoud, M.D.
  • Chief Medical Officer
  • 26.61K
  • Richard J. Berman
  • Chairman of the Board
  • 149.20K
  • Jennifer Evans Stacey, Esq.
  • Independent Director
  • 97.31K
  • Linda West
  • Independent Director
  • 100.81K
  • Dr. Philip Kantoff, M.D.
  • Independent Director
  • 80.81K

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
%Chg